Rash News and Research

RSS

People with celiac disease have reactions to non-gluten wheat proteins

Although gluten-free foods are trendy among the health-conscious, they are necessary for those with celiac disease. But gluten, the primary trigger for health problems in these patients, may not be the only culprit. Scientists are reporting in ACS' Journal of Proteome Research that people with the disease also have reactions to non-gluten wheat proteins. The results could help scientists better understand how the disease works and could have implications for how to treat it.

6 Nov 2014

UNMC researcher receives $3.3 million grant to study rare diseases that affect children

University of Nebraska Medical Center researcher, William Rizzo, M.D., has received a five-year, $3.3 million grant to study 10 rare diseases that affect children beginning in infancy or early childhood and throughout their life.

20 Oct 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

Web-based system could help improve detection of disease outbreaks, say researchers

A web-based system that allows preschools and child care centers to report illnesses to local public health departments could improve the detection of disease outbreaks and allow resources to be mobilized more quickly, according to University of Michigan research to be presented Saturday, Oct. 11 at the American Academy of Pediatrics (AAP) National Conference & Exhibition in San Diego.

13 Oct 2014

Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

In rare cases, patients with allergies to metals develop persistent skin rashes after metal devices are implanted near the skin. New research suggests these patients may be at increased risk of an unusual and aggressive form of skin cancer.

10 Oct 2014

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history.

1 Oct 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

State highlights: N.C. lawmakers still talking about Medicaid revamp; changes to La. health plan for state workers stir controversy

Legislators who couldn't agree this year on how to overhaul North Carolina's Medicaid program plan to spend more time talking about the issue before the General Assembly reconvenes early next year. A legislative oversight panel subcommittee charged with examining Medicaid reform and reorganization scheduled its first meeting Wednesday. Another oversight panel also examining Medicaid governance held its first meeting this month. The House and Senate approved differing versions of legislation to change how Medicaid pays for medical expenses by shifting risk from the state to either medical provider networks or private managed-care companies (9/24).

26 Sep 2014

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show.

24 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with an intense, red, itchy rash on their outer genital organs may be at increased risk of developing urinary tract infections (UTIs), according to new research from Wake Forest Baptist Medical Center. The treatment may be as simple as better hygiene and avoiding potential irritants such as bubble baths and swimming pools.

22 Aug 2014

Communications about the benefits of vaccination influence parents' intentions to immunize children

How do parents decide whether to vaccinate their child? In a study designed to formally look at the content of parent-targeted communications about the benefits of vaccination for measles, mumps and rubella, Indiana University School of Medicine investigators report that the framing of these messages influences parents' intentions to immunize their children.

19 Aug 2014

Topical sunscreens are still the safe option for sun protection

From lotions to sprays to sticks, consumers already have a myriad of options to choose from when selecting a sunscreen.

8 Aug 2014

Dermatologist warns about safety of children's skin care products

Before the advent of Internet search engines, parents obtained much of their medical advice from their child's doctor.

8 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014